{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T21:14:53Z","timestamp":1713474893280},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T00:00:00Z","timestamp":1265068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:sec><jats:label \/><jats:p> <jats:italic>Aliment Pharmacol Ther<\/jats:italic>\u2002<jats:bold>31<\/jats:bold>, 991\u20131000<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Nocturnal heartburn is common in patients with gastro\u2010oesophageal reflux disease (GERD).<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To compare the effects of single doses of rabeprazole 20\u2003mg and pantoprazole 40\u2003mg on 24\u2010h intragastric acidity and oesophageal acid exposure (OAE).<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 52 subjects with GERD and a \u22656\u2010month history of heartburn were randomized into a blinded, 2\u2003\u00d7\u20032 crossover trial. Subjects\u2019 intragastric pH was monitored in two 48\u2010h study periods with 6\u2010 to 13\u2010day washout between periods. Patients received placebo on day 1, a single dose of rabeprazole 20\u2003mg or pantoprazole 40\u2003mg on day 2, and standardized meals throughout.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The mean percentage time with intragastric pH &gt;4 was significantly greater with rabeprazole vs. pantoprazole for the 24\u2010h postdose interval (44.0% vs. 32.8%; <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). Significant differences were observed in the daytime (51.0% vs. 42.2%; <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001) and nighttime (32.0% vs. 16.9%; <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). Rabeprazole was also significantly superior in other intragastric pH parameters. There was no statistical difference for OAE between treatments.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> In GERD patients with nocturnal heartburn, rabeprazole 20\u2003mg was significantly more effective than pantoprazole 40\u2003mg in percentage time with intragastric pH &gt;4 during the nighttime, daytime, and 24\u2010h periods. Differences between treatments in OAE were not demonstrated. This trial is registered with <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">http:\/\/clinicaltrials.gov<\/jats:ext-link>, number NCT00237367.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2010.04255.x","type":"journal-article","created":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T08:35:55Z","timestamp":1265099755000},"page":"991-1000","source":"Crossref","is-referenced-by-count":8,"title":["Effects of a single dose of rabeprazole 20\u2003mg and pantoprazole 40\u2003mg on 24\u2010h intragastric acidity and oesophageal acid exposure: a randomized study in gastro\u2010oesophageal reflux disease patients with a history of nocturnal heartburn"],"prefix":"10.1111","volume":"31","author":[{"given":"P.","family":"MINER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"DELEMOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"XIANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"LOCOCO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"IENI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.1.45"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.07531.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200501000-00021"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01588.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363010-00006"},{"key":"e_1_2_7_7_2","first-page":"11","article-title":"Synthesis or rupture: duration of acid inhibition by proton pump inhibitors","volume":"39","author":"Sachs G","year":"2003","journal-title":"Drugs Today (Barc)"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02163.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.36.22438"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02176.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80032-6"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01496.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00002"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.03196.x"},{"key":"e_1_2_7_15_2","volume-title":"Memorandum: Memo to Customers Using Medtronic SlimlineTM or Zinetics24 Single\u2010use pH Catheters","author":"Bombeck T","year":"2005"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03790.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v9.i11.2583"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01292.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024703504585"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01535789"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026608804938"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850171828"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00419.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2001.02617.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04255.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2010.04255.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:22:25Z","timestamp":1698783745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04255.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,5]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1365-2036.2010.04255.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04255.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,5]]}}}